Want to see SE:BOUL full AI Analyst Report?
BOUL Stock Chart & Stats
kr1.03
kr0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Rangekr0.94 - kr6.64
Previous CloseN/A
VolumeN/A
Average Volume (3M)121.98K
Market Cap
kr40.19M
Enterprise Valuekr293.09M
Total Cash (Recent Filing)kr13.50M
Total Debt (Recent Filing)kr216.50M
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Feb 10, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.06%
Share Statistics
EPS (TTM)-0.45
Shares Outstanding38,833,103
10 Day Avg. Volume278,377
30 Day Avg. Volume121,983
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)1.11
Price to Sales (P/S)0.38
P/FCF Ratio-45.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.25
Revenue Forecast (FY)kr453.10M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables ModelThe installed-base model can create recurring consumables revenue after analyzer placement, improving customer retention and revenue visibility. Service and support activities add another ongoing revenue stream, giving Boule a durable monetization layer beyond one-time instrument sales.
Resilient Gross MarginMaintaining gross margin near 43–45% despite weaker revenue and operating performance indicates that the underlying product economics have not fully deteriorated. This provides a foundation for future margin recovery if sales stabilize and fixed costs are better absorbed.
Improving Cash GenerationThe recent rebound in operating cash flow and return to positive free cash flow improve Boule’s ability to fund operations internally. If sustained, this could reduce dependence on external financing and support investment in its analyzer platform and installed base.
Bears Say
Sustained Revenue DeclineThree consecutive periods of declining revenue signal persistent pressure on demand, pricing, or market execution rather than a single-quarter setback. Continued contraction can weaken scale benefits, reduce reinvestment capacity, and make recovery in operating profitability more difficult.
Persistent LossesSustained net losses show that Boule has not converted its medical technology offering into dependable earnings in recent periods. Ongoing losses can constrain strategic flexibility, consume equity, and make the recent improvement in cash flow less convincing until profitability returns.
Higher LeverageHigher debt relative to a shrinking equity base reduces financial flexibility and increases the burden on future operating cash flow. This leaves less capacity to absorb continued volatility or fund growth internally, particularly while accounting losses remain unresolved.
Boule Diagnostics AB News
BOUL FAQ
What was Boule Diagnostics AB’s price range in the past 12 months?
Boule Diagnostics AB lowest stock price was kr0.94 and its highest was kr6.64 in the past 12 months.
What is Boule Diagnostics AB’s market cap?
Boule Diagnostics AB’s market cap is kr40.19M.
When is Boule Diagnostics AB’s upcoming earnings report date?
Boule Diagnostics AB’s upcoming earnings report date is Feb 10, 2027 which is in 101 days.
How were Boule Diagnostics AB’s earnings last quarter?
Boule Diagnostics AB released its earnings results on Oct 23, 2026. The company reported -kr0.064 earnings per share for the quarter, missing the consensus estimate of -kr0.02 by -kr0.044.
Is Boule Diagnostics AB overvalued?
According to Wall Street analysts Boule Diagnostics AB’s price is currently Undervalued.
Does Boule Diagnostics AB pay dividends?
Boule Diagnostics AB pays a Annually dividend of kr0.389 which represents an annual dividend yield of 1.06%. See more information on Boule Diagnostics AB dividends here
What is Boule Diagnostics AB’s EPS estimate?
Boule Diagnostics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Boule Diagnostics AB have?
Boule Diagnostics AB has 38,833,103 shares outstanding.
What happened to Boule Diagnostics AB’s price movement after its last earnings report?
Boule Diagnostics AB reported an EPS of -kr0.064 in its last earnings report, missing expectations of -kr0.02. Following the earnings report the stock price went down -40.244%.
Which hedge fund is a major shareholder of Boule Diagnostics AB?
Currently, no hedge funds are holding shares in SE:BOUL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Boule Diagnostics AB
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, and Medonic brands; and veterinary hematology and clinical chemistry analyzer systems, as well as reagents and panels under the Exigo brand. It serves small and medium-sized hospitals, clinics, laboratories, and veterinary clinics, and other diagnostics firms. The company was founded in 1956 and is headquartered in Spånga, Sweden.